Author

C. V. Bitirim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. OZKUL· 2 shared A. YILMAZER· 2 shared C. GURCAN· 2 shared E. DEMIR· 2 shared E. KOCAKAYA· 2 shared G. Y. SUMMAK· 2 shared H. NAZIR· 2 shared J. SOMERS· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. OZKUL

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Hemin shows antiviral activity in vitro, possibly through suppression of viral entry mediators.

M. A. UNAL, C. V. BITIRIM, J. SOMERS, G. Y. SUMMAK, O. BUL BESBINAR, E. KOCAKAYA, C. GURCAN, H. NAZIR, Z. B. Aksoy Ozer, S. A. OZKAN, S. BEREKETOGLU, A. OZKUL, E. DEMIR, K. C. AKCALI, A. YILMAZER

This study shows Hemin reduces SARS-CoV-2 infectivity in Vero E6 cells by decreasing TMPRSS2 and ACE2 expression.

bioRxiv · May 24, 2022 · PreprintPharmacology & Toxicology

Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro

M. A. Unal, C. V. Bitirim, G. Y. Summak, S. Bereketoglu, I. Cevher Zeytin, O. Besbinar, C. Gurcan, D. Aydos, E. Goksoy, E. Kocakaya, Z. Eran, M. Murat, N. Demir, J. Somers, E. Demir, , K. C. Akcali

bioRxiv · Dec 4, 2020Pharmacology & Toxicology